Drugs / L-carnitine
L-carnitine
also known as
Levocarnitine · Carnitene · carnitine · Carnitor · L-Carnitina · L-carnitine hydrochloride · L-carnitine tartrate · L-carnitine: Carnitor
Other / unclassified targets PPARG
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | CARNITOR | — | 1992-12-16 – 1999-12-15 | fda.gov ↗ |
| Approved | US (FDA) | CARNITOR | — | 1985-12-27 | fda.gov ↗ |
Trials 75 · started per year
today
US approved 1985
3
2
1
2
2
3
4
3
4
2
2
3
5
7
4
3
2
3
6
4
6
3
19851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07201714 | Nov 2025 → Dec 2026 expected | disorder of carnitine cycle and carnitine transport, heart failure | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 0 | NCT05948124 | Aug 2023 → Feb 2024 | disorder of fatty acid and ketone body metabolism | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT05501899 | Mar 2023 → Dec 2024 overdue | acute lymphoblastic leukemia, poisoning | Children's Hospital of Orange County | Recruiting | No outcome recorded |
| Phase 0 | NCT06198803 | Jan 2022 → Jan 2024 | disorder of carnitine cycle and carnitine transport | Ain Shams University | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT05355311 | Sep 2024 → May 2025 | alcohol-related disorders | Brown University | Completed | No outcome recorded |
| Phase 1 | NCT01825369 | Dec 2014 → Jul 2020 | atrioventricular septal defect, ventricular septal defect | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 1 | NCT01193777 | Sep 2010 → Feb 2012 | infectious disease with sepsis | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03014882 | Feb 2015 → Dec 2017 | DNA repair disease, endocrine system disorder, male infertility | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00661453 | Apr 2008 → May 2012 | spinal muscular atrophy, type 1 | University of Utah | Completed | No outcome recorded |
| Phase 226 trials · 4 missed | ||||||
| Phase 2 | NCT07567274 | May → Jul 2026 overdue | tinnitus | Leading Edge Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06960694 | Jun → Nov 2025 | osteoarthritis, knee | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT06564909 | Jun 2025 → Dec 2026 expected | myocardial stunning | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06753565 | Dec 2024 → Jun 2025 overdue | rheumatoid arthritis | German University in Cairo | Recruiting | No outcome recorded |
| Phase 2 | NCT03953703 | Nov 2021 → Sep 2025 | Sjogren syndrome, keratoconjunctivitis | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT07249229 | Nov 2020 → Feb 2021 | end stage renal failure | Darya Chamani | Completed | No outcome recorded |
| Phase 2 | NCT04044131 | Dec 2019 → Mar 2021 | Alzheimer disease, Parkinson disease | Istanbul Medipol University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04086212 | Oct 2019 → Dec 2022 | end stage renal failure | Iperboreal Pharma Srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT04001036 | Sep 2019 → Aug 2022 | end stage renal failure | Iperboreal Pharma Srl | Terminated | No outcome recorded |
| Phase 2 | NCT04330326 | Jul 2019 → Jul 2020 | NAFLD1 | ScandiBio Therapeutics AB | Completed | No outcome recorded |
| Phase 2 | NCT03436277 | Dec 2018 → Feb 2019 | — | University of Guadalajara | Unknown | No outcome recorded |
| Phase 2 | NCT04145245 | Apr 2018 → Dec 2019 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT03108963 | Jan 2017 → Mar 2018 | polycystic ovary syndrome | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT01617772 | Jan 2016 → Oct 2019 | metabolic dysfunction-associated steatohepatitis | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02421887 | Dec 2015 → Jun 2018 | male infertility | Yale University | Completed | Missed primary |
| Phase 2 | NCT01665092 | Jan 2013 → Mar 2018 | infectious disease with sepsis | University of Mississippi Medical Center | Completed | Missed primary |
| Phase 2 | NCT01232907 | Oct 2010 → Apr 2013 | spinal cord injury | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT01278693 | Aug 2009 → Sep 2010 | dialysis disequilibrium syndrome | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00851838 | Jun 2009 → Oct 2012 | end stage renal failure | Iperboreal Pharma Srl | Completed | No outcome recorded |
| Phase 2 | NCT00858182 | May 2009 → Oct 2012 | end stage renal failure | Iperboreal Pharma Srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT00755456 | Jan 2008 → Sep 2012 | end stage renal failure | Iperboreal Pharma Srl | Completed | Missed primary |
| Phase 2 | NCT00755404 | Jun 2007 → Oct 2013 | diabetes mellitus, end stage renal failure | Iperboreal Pharma Srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT00227266 | Sep 2005 → Nov 2007 | spinal muscular atrophy | University of Utah | Completed | Missed primary |
| Phase 2 | NCT00922701 | Jun → Oct 2004 | end stage renal failure | Iperboreal Pharma Srl | Completed | No outcome recorded |
| Phase 2 | NCT00079599 | Nov 2002 → Mar 2007 | AIDS | National Institute of Nursing Research (NINR) | Completed | No outcome recorded |
| Phase 2 | NCT00034450 | Jan 2002 → Aug 2004 | neoplasm | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07669402 | Dec 2023 → Feb 2026 | oligoasthenoteratozoospermia | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT05817799 | Jan → Jul 2023 | — | Bahria University | Completed | No outcome recorded |
| Phase 2/3 | NCT04573153 | Sep 2020 → May 2022 | COVID-19 | ScandiBio Therapeutics AB | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03180424 | Jan → Aug 2017 | carnitine deficiency, myopathic | Hospital de Clínicas Dr. Manuel Quintela | Unknown | No outcome recorded |
| Phase 2/3 | NCT01783041 | Jan 2013 → Dec 2020 | disorder of carnitine cycle and carnitine transport, neurodevelopmental disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00247975 | Mar 2006 → Oct 2010 | heart failure | Ottawa Heart Institute Research Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 310 trials | ||||||
| Phase 3 | NCT07402759 | Jan → Jun 2026 overdue | oligoasthenoteratozoospermia | South Valley University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05905692 | May → Dec 2023 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT05632549 | Aug 2022 → Aug 2024 | asthma | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT03696940 | May 2018 → Mar 2019 | hyperlipidemia | Laboratorios Grossman, S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT02664753 | Mar 2018 → Dec 2024 | acute kidney injury, infectious disease with sepsis | Nîmes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT01786824 | Dec 2014 → Aug 2015 | acute kidney injury, impaired renal function disease | Nîmes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT01149525 | Jun 2010 → Mar 2013 | multiple sclerosis | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT00322322 | Jun 2006 → Jun 2010 | thyroid hormone metabolism, abnormal | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01549847 | ? → Feb 2013 | postpoliomyelitis syndrome | Biolab Sanus Farmaceutica | Withdrawn | No outcome recorded |
| Phase 3 | NCT00002220 | — | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07160452 | Sep 2025 → Mar 2026 overdue | anemia, end stage renal failure, kidney failure | Shaikh Zayed Hospital, Lahore | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06901323 | Feb 2025 → Mar 2026 overdue | phenylketonuria | Mansoura University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06849115 | Jul → Dec 2024 | amyotrophic lateral sclerosis | ChaodongWang | Completed | No outcome recorded |
| Phase 4 | NCT05673239 | Jan → Jun 2023 | — | The First Affiliated Hospital of Zhejiang Chinese Medical University | Completed | No outcome recorded |
| Phase 4 | NCT05322447 | Apr → Aug 2022 | respiratory failure | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03630367 | Oct 2018 → Sep 2020 | — | Assiut University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03604016 | Sep 2018 → Jul 2020 | hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT03630341 | Feb 2016 → Mar 2018 | polycystic ovary syndrome | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT00754767 | Jan 2007 → Apr 2008 | breast cancer, chemotherapy-induced neuropathy, toxic polyneuropathy | HealthPartners Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00173706 | Oct 2004 → ? | anemia, heart disorder, hypotensive disorder, myopathy | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00202228 | Jul 2002 → Oct 2008 | AIDS, lactic acidosis, lipodystrophy | Queen's University | Completed | No outcome recorded |
| Phase not applicable13 trials · 1 missed | ||||||
| — | NCT07437391 | Jan → Jun 2026 overdue | respiratory distress syndrome in premature infants | Muhammad Aamir Latif | Recruiting | No outcome recorded |
| — | NCT07266259 | Sep 2025 → Aug 2026 overdue | polycystic ovary syndrome | Mst.Sumyara Khatun | Recruiting | No outcome recorded |
| — | NCT06689501 | Oct 2024 → Jun 2025 | morbid obesity | Nestlé | Completed | No outcome recorded |
| — | NCT06042738 | Mar → Nov 2021 | male infertility | Ondokuz Mayıs University | Completed | No outcome recorded |
| — | NCT04672720 | Mar 2020 → Dec 2022 | polycystic ovary syndrome | Royan Institute | Completed | Missed primary |
| — | NCT03230812 | Mar 2018 → Nov 2019 | glucose intolerance | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT03476356 | Nov 2017 → Mar 2018 | polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| — | NCT03660293 | Apr 2017 → Jun 2019 | type 1 diabetes mellitus | Tanta University | Completed | No outcome recorded |
| — | NCT03372772 | Mar → Dec 2017 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| — | NCT02722902 | May 2016 → Jun 2017 | glucose intolerance | Maastricht University Medical Center | Terminated | No outcome recorded |
| — | NCT02322697 | Aug 2013 → Oct 2014 | disorder of fatty acid and ketone body metabolism | Toujinkai Hospital | Completed | No outcome recorded |
| — | NCT01231828 | Sep 2009 → Jun 2012 | cirrhosis of liver | University Hospital, Caen | Completed | No outcome recorded |
| — | NCT00841295 | Jul 2008 → Mar 2013 | — | University Hospital, Tours | Completed | No outcome recorded |
| Comparator or background therapy37 trials | ||||||
| Phase 0 | NCT06342856 Comparator | Jun 2023 → Jun 2024 | oligospermia | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT05487781 Background | May → Jun 2022 | — | Molecule X LLC | Unknown | No outcome recorded |
| Phase 0 | NCT03953248 Comparator | Jan 2016 → Jan 2018 | poisoning | Heba Allah Ali Abd El-Halim Mabrouk | Completed | No outcome recorded |
| Phase 2 | NCT07216001 Background | May 2026 → Dec 2027 expected | autism, childhood apraxia of speech | Claudia R. Morris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07108777 Comparator | Aug 2025 → Aug 2026 overdue | cisplatin toxicity | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT03164421 Comparator | Jan 2017 → Jun 2018 | polycystic ovary syndrome | Zagazig University | Completed | Missed primary |
| Phase 2 | NCT00481013 Comparator | Jul 2007 → Dec 2009 | spinal muscular atrophy | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00809042 Comparator | Jun → Nov 2007 | beta-thalassemia intermedia | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00002184 Background | — | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00000912 Background | ? → May 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00000885 Background | ? → Jun 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT00001087 Background | ? → Jul 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00002379 Background | — | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00002219 Background | — | HIV infectious disease | Gilead Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03021876 Comparator | Apr 2016 → Apr 2018 | — | Kochi University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01580553 Comparator | Jan 2011 → Mar 2012 | heart failure | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 3 | NCT05792527 Comparator | Mar 2023 → Mar 2025 | rheumatoid arthritis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05584956 Comparator | Jul 2022 → Jul 2023 | beta thalassemia | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT03426722 Comparator | Mar 2018 → Dec 2019 | gastrointestinal stromal tumor | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02792088 Background | Jul 2015 → Feb 2020 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02007889 Comparator | Nov 2013 → Aug 2014 | acute pyelonephritis | Shahid Beheshti University | Unknown | No outcome recorded |
| Phase 3 | NCT01671384 Comparator | Aug 2013 → Dec 2016 | spinal muscular atrophy | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01107730 Comparator | Apr 2010 → Apr 2015 | atrial fibrillation | Attikon Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00001082 Background | Dec 1996 → Jan 1999 | HIV infectious disease, cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT07862725 Background | Oct 2026 → Oct 2027 expected | oligoasthenoteratozoospermia | Hamad Medical Corporation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07642076 Comparator | Jun → Dec 2026 expected | liver disorder | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT04202536 Background | May 2019 → Jun 2021 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT04434404 Comparator | Sep 2018 → Aug 2019 | breast cancer | Horus University | Completed | No outcome recorded |
| Phase 4 | NCT05081349 Comparator | Jan 2017 → Jun 2020 | sickle cell disease | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT01769157 Comparator | Aug 2012 → Jun 2013 | hypothyroidism | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01665547 Comparator | Jul 2012 → Aug 2013 | — | Woman's Health University Hospital, Egypt | Unknown | No outcome recorded |
| — | NCT07016867 Comparator | Sep 2024 → Aug 2025 overdue | spermatogenic failure | South Valley University | Recruiting | No outcome recorded |
| — | NCT06122012 Background | May 2023 → Apr 2024 | diabetic polyneuropathy | Haisco Pharmaceutical Group Co., Ltd. | Unknown | Met primary |
| — | NCT05083637 Comparator | Oct 2021 → Mar 2023 | protein-energy malnutrition | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| — | NCT01523106 Comparator | Aug 2013 → Feb 2014 | Crohn disease | University of California, San Francisco | Withdrawn | No outcome recorded |
| — | NCT00002398 Background | — | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| — | NCT00000892 Background | ? → Aug 1999 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-10 | Saptalis Pharmaceuticals LLC | Regulatory Received FDA approval for its ANDA for Levocarnitine Oral Solution saptalis.com ↗
Saptalis Pharmaceuticals, LLC announced today that it has received FDA approval for its ANDA for Levocarnitine Oral Solution 1gm/10mL. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-10 | Saptalis Pharmaceuticals LLC | Received FDA approval for its ANDA for Levocarnitine Oral Solution saptalis.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 117 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-carnitine | “L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day...” NCT04434404 ↗92“food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg...” NCT06042738 ↗ “Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU,...” NCT02421887 ↗ “The purpose of the study to assess the efficacy of adding L-carnitine to clomiphene citrate for increasing the ovulation and the pregnancy rate in women with PCOS.” NCT03476356 ↗ “This group will receive the standard chemotherapy protocol (cisplatin -based chemotherapy) plus L-carnitine 350 mg (L-carnitine®) three times daily by oral.” NCT07108777 ↗ “Participants will receive antioxidant therapy consisting of vitamin C 1000 mg/day, vitamin E 400 IU/day, L-carnitine, and zinc 25 mg/day for 6 months.” NCT07862725 ↗ “Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients.” NCT00858182 ↗ “The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up” NCT05083637 ↗ “The study product is blend of ingredients composed of L-carnitine tartrate, dihydrocapsiate and protein yeast hydrolysate (DNF-10®).” NCT06689501 ↗ “First, the investigators will include L-carnitine to enhance the transport of fatty acids across the mitochondrial membrane” NCT04330326 ↗ “L-carnitine is an important factor in fatty acid metabolism, and carnitine deficiency is common in dialysis patients.” PMID 33139659 ↗ Nov 2020 |
| Known as | Carnitene | “All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.” NCT03230812 ↗ |
| Known as | carnitine | “Carnitine is the essential cofactor for various enzyme activities of human metabolism, especially for the mitochondrial carnitine shuttle that transfers long-chain fatty acids...” NCT00841295 ↗ |
| Known as | Carnitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02722902 ↗ |
| Known as | L-Carnitina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05487781 ↗ |
| Known as | L-carnitine hydrochloride | “HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；” NCT06122012 ↗ |
| Known as | L-carnitine tartrate | “Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).” NCT04573153 ↗ |
| Known as | L-carnitine: Carnitor | “L-carnitine: Carnitor” NCT00202228 ↗ |
| Known as | Levocarnitine | “Several experimental studies have shown that levocarnitine reduces myocardial injury after ischemia and reperfusion by counteracting the toxic effect of high levels of free...” PMID 15591005 ↗ Nov 200427“Levocarnitine (L-carnitine) is a micronutrient found in meat and dairy products that plays a major role in energy metabolism.” NCT00079599 ↗ “All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.” NCT03230812 ↗ “Drug: Valproic Acid and Levocarnitine; capsules” NCT00481013 ↗ |
| Modality | Other / unclassified | “L-carnitine is an amino acid derivative that is thought to be helpful for treating renal anemia in hemodialysis patients.” PMID 33713287 ↗ Mar 2021 |
| Route | Oral | “500 mg tablet taken orally daily” NCT00001082 ↗ |
| Target | PPARG | “LC also have anti-inflammatory effect by acting on PPAR gamma” NCT06753565 ↗ |